

EPA Comments on the SAB Draft Peer Review Report on Hexahydro-1,3,5-trinitro- 1,3,5-triazine (RDX)

Science Advisory Board - Chemical
Assessment Advisory Committee
Teleconference

April 13 and 17, 2017

A large, faint watermark of the EPA logo is centered in the background. It features a stylized flower with three leaves and a circular center, surrounded by the text "UNITED STATES ENVIRONMENTAL PROTECTION AGENCY" in a circular arrangement.


EPA Opening Remarks

April 13th Discussion Topics

- Literature Search/Study Selection and Evaluation
 - Incorporation of metabolites and breakdown products to evaluate RDX toxicity.


April 13th Discussion Topics

- Toxicokinetic Modeling
 - *No clarification requested by EPA.*




April 13th Discussion Topics

- Cancer
 - *No clarification requested by EPA.*




April 13th Discussion Topics

- Oral Slope Factor for Cancer
 - *No clarification requested by EPA.*



April 13th Discussion Topics

- Developmental and Reproductive System Effects
 - *No clarification requested by EPA.*



Clarifying Remarks and Action Items



April 17th Discussion Topics

- Nervous System Effects
 - Evaluation of additional endpoints for nervous system effects (other than seizures/convulsions)
 - Confidence in, and use of, the Cholakis et al. (1980) technical report.
 - Study quality considerations (single incident of convulsion in positive control group)
 - Use of Cholakis in addition to the data from Crouse et al. (2006).

April 17th Discussion Topics


- Nervous System Effects (cont'd)
 - Identification of a point of departure for nervous system effects/selection of the BMR.
 - Interpretation of BMD technical guidance and application to Crouse et al. (2006) dataset.

April 17th Discussion Topics

- Kidney and other Urogenital System Effects
 - Sufficiency of weight-of-evidence (independent of kidney effects) for identifying the prostate as a hazard of RDX exposure.
 - What prostate endpoint would be most appropriate for analysis (suppurative or all types of prostatitis combined)?


April 17th Discussion Topics

- Other Noncancer Hazards
 - *No clarification requested by EPA.*




April 17th Discussion Topics

- Oral Reference Dose
 - *No clarification requested by EPA.*




April 17th Discussion Topics

- Inhalation Reference Concentration
 - *No clarification requested by EPA.*




April 17th Discussion Topics

- Inhalation Unit Risk for Cancer
 - *No clarification requested by EPA.*




April 17th Discussion Topics

- Executive Summary (sec. 3.5)
 - *No clarification requested by EPA.*




April 17th Discussion Topics

- Executive Summary (Sec. 1.0)
 - *No clarification requested by EPA.*




April 17th Discussion Topics

- Letter to the Administrator
 - *No clarification requested by EPA.*



April 17th Discussion Topics

- Appendix C
 - *No clarification requested by EPA.*



A large, faint watermark of the Environmental Protection Agency (EPA) logo is centered in the background. The logo consists of a circular border containing the text "UNITED STATES" at the top and "ENVIRONMENTAL PROTECTION AGENCY" at the bottom. In the center of the circle is a stylized flower with three leaves and a circular center.

Clarifying Remarks and Next Steps